Applied Clinical Trials

Applied Clinical Trials magazine is an internationally recognized, peer-reviewed publication that focuses on the management of clinical trials. It highlights the collaboration between pharmaceutical developers and the medical researchers who conduct rigorous tests on new medications, all within a tightly regulated environment.

National

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

#704116

United States

#374877

Health/Biotechnology and Pharmaceuticals

#316

Traffic sources

Monthly visitors

Articles

How CRO Partnerships Are Evolving to Meet Changing Industry Demands

3 days ago | appliedclinicaltrialsonline.com | Andy Studna

In a recent video interview with Applied Clinical Trials, Judith Ng-Cashin, MD, chief medical officer, Novotech discussed the company’s recent accomplishment of winning the Citeline CRO Partnership of the Year Award in recognition of its partnership with Tune Therapeutics.
How CROs Can Build Trust and Alignment with Pharma Partners

4 days ago | appliedclinicaltrialsonline.com | Andy Studna

June 24, 2025By In this video interview, Judith Ng-Cashin, MD, chief medical officer, Novotech, emphasizes the importance of proactive communication, strategic alignment, and cross-functional collaboration in establishing strong, effective partnerships between CROs and pharmaceutical companies.
Fostering a Unified Team Culture in Sponsor and CRO Partnerships

5 days ago | appliedclinicaltrialsonline.com | Andy Studna

June 23, 2025By In this video interview, Judith Ng-Cashin, MD, chief medical officer, Novotech, shares insights on how sponsors and CROs can cultivate a “one team” mindset by setting the right leadership tone, encouraging collaboration, and leveraging team-building strategies to drive clinical trial success.
Bridging Communication Gaps to Strengthen CRO-Sponsor Collaboration

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

June 20, 2025By In this video interview, Judith Ng-Cashin, MD, chief medical officer, Novotech, shares why clear communication, strong leadership, and cultural alignment are essential to building effective partnerships between CROs, sponsors, and other stakeholders in clinical research.
Phase III OASIS-4 Trial Shows Elinzanetant Significantly Reduces Endocrine Therapy-Related Vasomotor Symptoms in Patients with HR-Positive Breast Cancer

1 week ago | appliedclinicaltrialsonline.com | Davy James

Elinzanetant Significantly Reduces Vasomotor Symptoms. Patients receiving elinzanetant experienced a statistically significant reduction in moderate-to-severe vasomotor symptoms at both four and 12 weeks compared to placebo, with over 70% achieving at least a 50% symptom reduction. Improved Sleep and Quality of Life with Elinzanetant.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research

1 week ago | appliedclinicaltrialsonline.com | Don Tracy

At the DIA Annual Meeting, Peter Ronco, CEO, Emmes, emphasized the under-recognized but impactful role of the public sector—particularly the NIH and FDA—in advancing tech-enabled clinical development. These agencies have pioneered the use of AI and large language models for tasks such as automating IND submissions, optimizing protocol design, and leveraging decades of complex data to improve trial execution and patient recruitment.
2025 DIA Annual Meeting: Preparing Operational Teams for AI Workflows in Drug Development

1 week ago | appliedclinicaltrialsonline.com | Don Tracy

At the DIA Annual Meeting, Peter Ronco, CEO, Emmes, emphasized the underrecognized but impactful role of the public sector—particularly the NIH and FDA—in advancing tech-enabled clinical development. These agencies have pioneered the use of AI and large language models for tasks such as automating IND submissions, optimizing protocol design, and leveraging decades of complex data to improve trial execution and patient recruitment.
Building Strong CRO-Sponsor Partnerships to Improve Clinical Trial Success

1 week ago | appliedclinicaltrialsonline.com | Andy Studna

In a recent video interview with Applied Clinical Trials, Judith Ng-Cashin, MD, chief medical officer, Novotech discussed the company’s recent accomplishment of winning the Citeline CRO Partnership of the Year Award in recognition of its partnership with Tune Therapeutics.
Phase II TRANSCEND FL Shows Breyanzi Achieves Strong Efficacy, Durable Response in Relapsed Marginal Zone Lymphoma

1 week ago | appliedclinicaltrialsonline.com | Davy James

Breyanzi Achieves High Overall Response Rate in R/R MZL. In the Phase II TRANSCEND FL trial, Breyanzi demonstrated a 95.5% overall response rate and a 62.1% complete response rate in patients with relapsed or refractory marginal zone lymphoma (MZL). Durable Efficacy Observed in Long-Term Follow-Up. At median follow-ups nearing two years, Breyanzi showed an 88.6% duration of response, 85.7% progression-free survival, and 90.4% overall survival in the MZL cohort.
2025 DIA Annual Meeting: Designing Patient Friendly Digital Health Solutions

1 week ago | appliedclinicaltrialsonline.com | Don Tracy

In an interview with Applied Clinical Trials, Brian Ongioni, chief product officer, uMotif, discussed how the company actively incorporates patient and site feedback throughout the digital health product lifecycle to ensure its tools are both accessible and intuitive.